Abstract:Introduction The current treatment algorithm for Peyronie's Disease (PD) was updated in 2015 to exclude oral therapies. Non-surgical pharmacological management is now limited to intralesional therapy with Collagenase Clostridium Histolyticum (CCh), Interferon, or Verapamil. Surgical options include tunical plication, plaque incision/excision with or without grafting, and penile prosthesis surgery with or without adjunctive procedures. An understanding of trends in management of PD since the updated guidelines is limited. Objective Our objective is to assess treatment utilization and temporal trends in PD with the change in guidelines. Methods We conducted a retrospective review of men with PD using data in the IBM MarketScan insurance claims database. Patients were identified using ICD 9/10 codes and treatments were identified using J and CPT codes. Only patients aged ≥18 years with at least 1 year before and after a PD diagnosis were included in the analysis. Descriptive statistics were used to describe non-surgical and surgical treatment groups. Linear regressions were also performed to assess the trends of each year based on initial PD treatment. Results Between 2011-2019, we identified a total of 45,114 patients with a diagnosis of PD. Overall, while the majority (91.9%) chose conservative management with no intervention, 1,041 (2.3%) pursued intralesional therapy and 2,594 (5.8%) pursued surgical intervention as an initial treatment option. Among the patients who initially opted for intralesional therapy, 67 (6.4%) sought subsequent surgical treatment whereas 974 (93.6%) did not pursue additional treatment. In comparison, 116 (4.5%) patients who initially underwent surgical intervention sought subsequent treatment with the remaining 2,478 (95.5%) not pursuing additional treatment. Annual overall treatment rates increased from 7.2% to 8.1%. There was a statistically significant increase in the utilization of intralesional therapies from 0.3% in 2011 to 4.1% in 2019 (p=0). Surgical interventions significantly declined from 6.8% to 3.9% over the same time period (p=0.004). Conclusions The present study demonstrates that PD treatment trends have changed over time. With overall low secondary treatment rates for patients initially pursuing either non-surgical or surgical treatment options, a greater proportion of patients are initially pursuing less invasive, non-surgical treatment options with intralesional therapy over time. These findings emphasize the dynamic nature of treatment decisions and contribute to a deeper understanding of the treatment landscape that can be incorporated into patient counseling. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Paterna bio, Firmtech, Turtle health, Maximus, Carrot, Contraline, endo pharmaceuticals, inherent biosciences, techfields inc, macro trials, alto neurosciences, curebase, vivify medical.

The Advances in Non-Surgical Treatment of Peyronie's Disease

Non-invasive treatment in the management of Peyronie’s disease

МODERN NON-INVASIVE METHODS FOR TREATING PEYRONIE'S DISEASE

Molecular Mechanisms and Current Pharmacotherapy of Peyronie’s Disease: A Review

Acute Phase Peyronie's Disease: Where Do We Stand?

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Response to comment on: penile prosthesis implantation is safe and effective in Peyronie's disease patients with and without erectile dysfunction

Intralesional and topical treatments for Peyronie's disease: a narrative review of current knowledge

Research advances in Peyronie’s disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets

Comment on: Penile prosthesis implantation is safe and effective in Peyronie's Disease patients with and without erectile dysfunction

Intralesional and topical treatments for Peyronie’s disease: a narrative review of current knowledge

(401) Treatment Utilization and Temporal Trends in Peyronie's Disease: A Retrospective Analysis of an Insurance Claims Database

[New "conservative" treatments for Peyronie's disease-real alternatives or expensive pastime?]

[Replacement of Plaque by Buccal Mucosa in the Treatment of Peyronieś Disease: a Report of 27 Cases].

The Efficacy and Safety of Low‐Intensity Pulsed Ultrasound Therapy for the Treatment of Peyronie's Disease (A Report of 106 Cases): A Retrospective Study

Evidence of restorative therapies in the treatment of Peyronie disease: A narrative review

A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie's disease: clinical trial update

Grafts in Peyronie’s surgery without the use of prostheses: a systematic review and meta-analysis

Low-intensity extracorporeal shock wave therapy for Peyroniès disease: a systematic review and meta-analysis

Outcomes of surgical correction of Peyronie's disease with plaque excision and grafting: Comparison of testicular tunica vaginalis graft versus bovine pericardium graft

(239) Prp As A Therapeutic Option In Peyronie'S Disease